The goal of our studies is to generate durable CD8+ T cell responses against epithelial ovarian cancer (EOC) for extending remission rates. However, major obstacles to the development of effective immunotherapy exist including (i) inability to induce expansion of high avidity, tumor-antigen specific effector CD8+ T cells (ii) lack of tumor-antigen specific memory CD8+ T cells, and (iii) presence of CD4+CD25+FOXP3+ regulatory T cells. In previous studies, we have observed that although vaccine induced tumor antigen specific effector CD8+ T cells can provide tumor protection, they do not provide durable tumor immunity, which is typically afforded by memory T cells. We have also noted that rapamycin mediated inhibition of mammalian target of rapamycin (mTOR) switches effector CD8+ T cells to memory via regulation of transcriptional factors T-bet and Eomesodermin. Moreover, in our murine model, varying the duration (0-8, 0-20 or 0-40 days) of mTOR inhibition after immunization produces memory CD8+ T cells with varying extent of type 1 effector functions. Consequently, we hypothesize that by changing the regimen (dose and duration) of rapamycin administration in immunized ovarian cancer patients, we will generate high avidity CD8+ T cells with varying extent of effector functions for durable ovarian tumor immunity. Therefore, our objectives are to determine the regimen of mTOR inhibition, that in combination with viral vector immunization does not produce toxicity but generates optimal durable CD8+ T cell responses in a phase I clinical trial. Second, by varying the timing of rapamycin administration, we will determine the mechanisms by which mTOR inhibition produces functionally distinct memory CD8+ T cells of high avidity. To test our hypotheses, we propose: SA1: To determine the regimen (dose and duration) of mTOR inhibition that in combination with rCNP-NY-ESO-1/TRICOM immunization is safe and produces durable CD8+ T cell responses in a phase I clinical trial. SA2: To test whether the regimen of rapamycin administration after rCNP-NY-ESO-1/TRICOM immunization generates memory CD8+ T cells with varying extent of effector functions and antigen avidity. SA3: To determine the impact of rapamycin treatment regime on rCNP-NY-ESO-1/TRICOM induced CD4+ T cell response for CD8+ T cell memory generation. The successful completion of our proposed studies will result in the generation of critical data that will facilitate Phase II evaluation of mTOR inhibition to generate high avidity memory T cells, promote conditions that favor durable host immunity, and prolong disease free survival in ovarian cancer patients.

Public Health Relevance

There is increasing evidence that the immune system has the ability to recognize and kill ovarian and other human cancers. However, attempts at using cancer vaccines to engage the immune system to fight cancer cells have been disappointing because of (i) inability to generate long lasting immune responses (ii) suppression of immune cells by a specialized population of cells called regulatory T cells. In this study proposed, we plan to test a multi-modal approach of immunizing ovarian cancer patients by (i) using a viral based vaccine expressing three specialized molecules (TRICOM) to enhance immune reaction to NY-ESO-1 antigen, that is frequently expressed in ovarian cancers (ii) rapamycin to promote generation of memory immune cells that persist for a long time and thereby prevent relapse of ovarian cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA158318-03
Application #
8515757
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Song, Min-Kyung H
Project Start
2011-09-01
Project End
2016-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
3
Fiscal Year
2013
Total Cost
$318,433
Indirect Cost
$115,111
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Seagle, Brandon-Luke L; Eng, Kevin H; Yeh, Judy Y et al. (2016) Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer. Sci Rep 6:21591
Brightwell, R M; Grzankowski, K S; Lele, S et al. (2016) The CD47 "don't eat me signal" is highly expressed in human ovarian cancer. Gynecol Oncol 143:393-397
Chaudhuri, Leena; Srivastava, Rupesh K; Kos, Ferdynand et al. (2016) Uncoupling protein 2 regulates metabolic reprogramming and fate of antigen-stimulated CD8+ T cells. Cancer Immunol Immunother 65:869-74
Szender, J Brian; Eng, Kevin H; Matsuzaki, Junko et al. (2016) HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecol Oncol 142:158-62
Klinkebiel, David; Zhang, Wa; Akers, Stacey N et al. (2016) DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer. Mol Cancer Res 14:787-94
Zhang, Wa; Barger, Carter J; Link, Petra A et al. (2015) DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Epigenetics 10:736-48
Huang, Ruea-Yea; Eppolito, Cheryl; Lele, Shashikant et al. (2015) LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget 6:27359-77
Chodon, Thinle; Koya, Richard C; Odunsi, Kunle (2015) Active Immunotherapy of Cancer. Immunol Invest 44:817-36
Khan, Anm Nazmul H; Kolomeyevskaya, Nonna; Singel, Kelly L et al. (2015) Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer. Oncotarget 6:11310-26
Seagle, Brandon-Luke L; Yang, Chia-Ping Huang; Eng, Kevin H et al. (2015) TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas. Gynecol Oncol 138:159-64

Showing the most recent 10 out of 18 publications